Form 8-K - Current report:
SEC Accession No. 0001104659-23-029078
Filing Date
2023-03-06
Accepted
2023-03-06 17:02:07
Documents
12
Period of Report
2023-02-28
Items
Item 4.02: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm238624d1_8k.htm   iXBRL 8-K 31793
  Complete submission text file 0001104659-23-029078.txt   209345

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA anvs-20230228.xsd EX-101.SCH 3039
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE anvs-20230228_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE anvs-20230228_pre.xml EX-101.PRE 22599
6 EXTRACTED XBRL INSTANCE DOCUMENT tm238624d1_8k_htm.xml XML 3707
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39202 | Film No.: 23709746
SIC: 2834 Pharmaceutical Preparations